研究者情報

キクチ　エイジ   KIKUCHI EIJI   菊地栄次    所属   医学部医学科 腎泌尿器外科学    職種   主任教授
言語種別	日本語
発表タイトル	Effectiveness and treatment patterns in patients with advanced urothelial carcinoma receiving avelumab first-line (1L) maintenance in Japan: JAVEMACS
会議名	第112回日本泌尿器科学会総会
学会区分	全国規模の学会
発表形式	口頭
講演区分	シンポジウム・ワークショップ・パネル（その他）
発表者・共同発表者	Kitamura Hiroshi, Kobayashi Takashi, Kimura Go, Ikeda Masaomi, Yonemori Kan, Kawamura Norihiko, Fujihara Atsuko, Abe Takashige, Shimizu Fumitaka, Fujimoto Kiyohide, Nakagawa Tohru, Hatakeyama Shingo, Murakami Kaoru, Nishihara Kiyoaki, Ikarashi Daiki, Masumori Naoya, Kambe Anzu, Shono Michihiro, Shirotake Suguru, Kikuchi Eiji
発表年月日	2025/04/19
開催地 （都市, 国名）	福岡県福岡市
開催期間	2025/04/17～2025/04/19
概要	[Object] JAVEMACS study of avelumab 1L maintenance reports outcomes of patients with locally advanced/metastatic urothelial carcinoma (Ia/mUC) in Japan who have not progressed after 1L platinum-based chemotherapy (PBC). [Methods] A multicenter retrospective study reviewed medical charts of patients who started avelumab 1L maintenance (Feb 2021-Dec 2023) to assess patient characteristics, effectiveness, and treatment patterns. [Results] At data cutoff (Jun 2024), 350 patients were included. Median duration of avelumab 1L maintenance was 14.3 wks. At avelumab start, median age of patients was 73 y; 28.6% were cisplatin eligible (CE) and 52.9% were C ineligible/platinum eligible (CI/PE); 1L PBC was gemcitabine (G)+C (GC) in 55.9% and G+carboplatin (GCarbo) in 33.1%. Median values for OS (mOS), progression-free survival (mPFS) and mPFS2 from avelumab start were 31.8 mo, 7.4 mo, and 20.8 mo; mOS in CE and CI/PE patients were 31.2 mo and 31.8 mo; and mOS in patients treated with 1L GC and GCarbo were not reached and 24.3 mo, respectively. At data cutoff, 70.7% patients who discontinued avelumab received second-line (2L)- enfortumab vedotin (EV) 66.5%/PBC 20.5%/pembrolizumab 8.5%, with mOS from avelumab start of 31.8 mo, 23.5 mo, and 24.3 mo, respectively. [Conclusions] Avelumab 1L maintenance offers long-term OS benefits in patients with la/mUC without disease progression after 1L PBC in clinical practice in Japan, regardless of C eligibility. Despite no resistance to PBC, 2L EV was more common than 2L PBC post avelumab 1L maintenance, highlighting the evolving treatment landscape.